Browse the evidence

In the 10-mg tirzepatide group, 56% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 46 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

In the 5-mg tirzepatide group, 44% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 34 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

Intensive lifestyle modification decreased the incidence of diabetes by 6.2 cases per 100 person-years during a 3-year period.

Encouraging lifestyle changes can significantly reduce the risk of developing diabetes.

Intentional weight loss, particularly when substantial, lowers cardiovascular disease risk among people with overweight/obesity.

Weight management strategies should be emphasized in clinical practice to reduce CVD risk.

Treatment with once-weekly injectable semaglutide resulted in a mean change in body weight of -13.7% compared to -3.2% with placebo (P<0.001).

Semaglutide may be an effective treatment for weight loss in obese individuals with knee osteoarthritis.

Semaglutide treatment led to a mean change in the WOMAC pain score of -41.7 points compared to -27.5 points with placebo (P<0.001).

Semaglutide may significantly reduce pain in obese individuals with knee osteoarthritis.

Participants in the semaglutide group had a greater improvement in SF-36 physical-function score (mean change, 12.0 points) compared to the placebo group (mean change, 6.5 points; P<0.001).

Semaglutide may improve physical function in obese individuals with knee osteoarthritis.

Fewer antidiabetes medications were used in the bariatric surgery group compared to the medical/lifestyle management group.

Bariatric surgery may reduce the need for diabetes medications compared to lifestyle management.

Higher weight loss was associated with a lower hazard of discontinuation for both patients with and without type 2 diabetes.

Encouraging weight loss may improve adherence to GLP-1 RA therapy.

The mean weight loss after 3 months of semaglutide treatment was 6.7 kg, equivalent to 5.9%.

Practitioners can expect significant weight loss in patients treated with semaglutide over 3 months.

The mean weight loss after 6 months of semaglutide treatment was 12.3 kg, equivalent to 10.9%.

Practitioners can expect continued weight loss in patients treated with semaglutide over 6 months.

87.3% of patients achieved weight loss of 5% or more after 6 months.

Practitioners can expect a high proportion of patients to achieve at least 5% weight loss with semaglutide.

Total ultra-processed food (UPF) intake is associated with a 46% higher risk of type 2 diabetes (T2D) when comparing extreme quintiles of intake.

Reducing UPF consumption may lower the risk of developing type 2 diabetes.

Participants in the highest category for total whole grain consumption had a 29% lower rate of type 2 diabetes compared with those in the lowest category.

Encouraging higher whole grain consumption can be an effective strategy for reducing the risk of type 2 diabetes.

Pooled hazard ratios for type 2 diabetes were 0.81 for whole grain cold breakfast cereal and 0.79 for dark bread when comparing those consuming one or more servings a day to those consuming less than one serving a month.

Incorporating whole grain cold breakfast cereal and dark bread into the diet may significantly lower diabetes risk.

Increased physical activity was the most consistent positive correlate of weight loss maintenance.

Practitioners should emphasize the importance of physical activity in weight loss maintenance strategies.

The review identified 51 weight loss and maintenance strategies grouped in 14 domains.

Practitioners can utilize these identified strategies to enhance weight loss maintenance programs.

Omega-3 fatty acid supplementation attenuates the decline in muscle volume during two weeks of unilateral leg immobilization in healthy young women (14% decline in control vs. 8% in n-3 group, P < 0.05).

Practitioners may consider recommending omega-3 supplementation to mitigate muscle loss during periods of immobilization.

Integrated rates of myofibrillar protein synthesis (MyoPS) were higher in the n-3 group compared to the control group at all times (P < 0.05).

Higher MyoPS in the n-3 group suggests that omega-3 supplementation may enhance muscle recovery and growth.

Liraglutide, 3.0 mg, leads to a mean percentage body weight reduction of -8.82% compared to -0.54% with placebo over 24 weeks.

Liraglutide can be considered as an effective adjunct therapy for weight management in patients struggling after metabolic surgery.

Semaglutide 2.4 mg once weekly significantly reduces body weight by approximately 15%, with simultaneous improvement in cardiometabolic risk factors and physical functioning in people with obesity.

Practitioners can consider semaglutide as an effective treatment option for weight loss in obese patients.

Tirzepatide has recently demonstrated that body weight reduction exceeding 20% in people with obesity is feasible.

Tirzepatide may be considered for patients seeking substantial weight loss.

A personalized postprandial-targeting (PPT) diet improved glycemic control significantly more than a Mediterranean (MED) diet as measured by daily time of glucose levels >140 mg/dL and HbA1c.

Practitioners may consider recommending a PPT diet for better glycemic control in prediabetic patients.

Both the PPT and MED diets reduced the daily time with glucose levels >140 mg/dL and HbA1c levels, but reductions were significantly greater in the PPT group.

Both diets can be beneficial, but the PPT diet may be more effective for glycemic control.